Pharmaids H1 profit depends on Rs 4.20 crore exceptional item

Pharmaids Pharmaceuticals Limited reported consolidated profit of Rs 6.24 lakh for the half year ended September 30, 2026, after booking a Rs 4.20 crore exceptional item against a Rs 4.16 crore loss before exceptional items and tax. Pharmaids’ revenue from operations fell 45% year on year to Rs 8.46 crore.

Why did Pharmaids report a first-half profit?

Pharmaids reported a first-half profit because its Rs 4.20 crore exceptional item exceeded its Rs 4.16 crore loss before exceptional items and tax. The group reported profit before tax of Rs 4.11 lakh for the half year ended September 30, 2026, compared with a loss before tax of Rs 10.79 crore in the corresponding half year ended September 30, 2025. A deferred-tax credit of Rs 2.13 lakh resulted in consolidated profit of Rs 6.24 lakh.

The exceptional item was recognised entirely in the quarter ended June 30, 2026; the September 2026 quarter showed no exceptional item. The filing does not state the nature of the Rs 4.20 crore amount. Without that item, Pharmaids’ reported half-year result before tax would have remained a Rs 4.16 crore loss, meaning the profit was not generated by the result before exceptional items.

The prior-year first half also contained an exceptional item, of Rs 2.99 crore. However, Pharmaids still reported a Rs 7.81 crore consolidated loss for the half year ended September 30, 2025. The year-on-year shift to a Rs 6.24 lakh profit therefore reflects both a lower pre-exceptional loss and a larger exceptional item in the latest period.

How far did Pharmaids’ H1 revenue decline?

Pharmaids’ revenue from operations declined about 45% to Rs 8.46 crore in the half year ended September 30, 2026, from Rs 15.27 crore a year earlier. Total income, including other income, fell to Rs 8.56 crore from Rs 15.53 crore. Other income declined to Rs 10.39 lakh from Rs 26.16 lakh, so it did not materially offset the reduction in operating revenue.

The group reported Rs 4.12 crore of revenue from operations in the June 2026 quarter and Rs 4.34 crore in the September 2026 quarter. Revenue thus increased by Rs 21.42 lakh sequentially in the second quarter. The available comparable September 2025 quarter recorded Rs 8.61 crore, which was substantially above either quarter in the latest half year.

Pharmaids operates in one segment, contract research and manufacturing services, according to its notes to accounts. The filing consequently provides no product-level, customer-level or business-division revenue split. The movement from Rs 15.27 crore to Rs 8.46 crore is the disclosed group-level operating revenue comparison.

What changed in Pharmaids’ costs and quarterly earnings?

Pharmaids reduced total expenses to Rs 12.72 crore in the six months ended September 30, 2026, from Rs 29.31 crore in the previous corresponding period, but those expenses remained above total income of Rs 8.56 crore. Employee-benefit expense fell to Rs 4.96 crore from Rs 7.37 crore, other expenses declined to Rs 1.67 crore from Rs 7.54 crore, and finance costs reduced to Rs 1.26 crore from Rs 2.27 crore.

Cost of materials consumed fell to Rs 2.72 crore from Rs 12.27 crore, alongside the lower revenue base. Purchases of stock-in-trade decreased to Rs 1.03 crore from Rs 1.53 crore, while depreciation and amortisation expense reduced to Rs 97.54 lakh from Rs 1.07 crore. These cost movements narrowed the loss before exceptional items and tax to Rs 4.16 crore from Rs 13.78 crore, though the underlying result remained negative.

The two quarters produced different reported outcomes. Pharmaids recorded a loss before exceptional items and tax of Rs 1.79 crore in the June 2026 quarter and Rs 2.37 crore in the September 2026 quarter. The June quarter reported profit after tax of Rs 1.87 crore after the exceptional item, whereas the September quarter, without such an item, reported a loss after tax of Rs 1.81 crore.

What do Pharmaids’ balance sheet and cash flows show?

Pharmaids’ total assets were Rs 87.87 crore at September 30, 2026, compared with Rs 88.47 crore at March 31, 2026. Total equity declined to Rs 47.69 crore from Rs 49.49 crore, as other equity decreased to Rs 12.52 crore from Rs 14.60 crore. Paid-up equity share capital was unchanged at Rs 35.27 crore.

Borrowings increased over the six months. Non-current borrowings rose to Rs 14.95 crore at September 30 from Rs 12.06 crore at March 31, while current borrowings increased to Rs 10.55 crore from Rs 10.18 crore. Cash and cash equivalents were Rs 15.70 lakh at September 30, compared with Rs 14.19 lakh at March 31, and trade receivables declined to Rs 3.34 crore from Rs 3.78 crore.

Net cash generated from operating activities was Rs 1.89 lakh for the half year ended September 30, 2026, against net cash used in operations of Rs 3.73 crore a year earlier. Investing activities used Rs 95.33 lakh, including Rs 1.27 crore spent on property, plant, equipment and capital work-in-progress. Financing activities generated Rs 95.80 lakh after Rs 11.05 crore of borrowing proceeds and Rs 6.47 crore of borrowings repaid.

What did the auditor’s review say about Pharmaids’ results?

The independent reviewer said nothing had come to its attention suggesting that Pharmaids’ consolidated unaudited results did not make required disclosures or contained a material misstatement. The review report was dated November 11, 2026, and was issued under Regulation 33 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015.

The reviewer stated that its work was a review rather than an audit, and therefore did not provide audit assurance. The consolidated results included one subsidiary and one step-down subsidiary whose interim results were reviewed by other auditors. Those entities had total assets of Rs 36.65 crore at September 30, 2026, revenue of Rs 7.40 crore and net loss after tax of Rs 95.06 lakh for the half year.

The reviewer relied on the reports of those other auditors for the relevant subsidiary amounts and said its conclusion was not modified on that basis. Pharmaids’ named subsidiaries in the review report were Adita Bio Sys Private Limited and Spring Labs, the step-down subsidiary. The Board approved the consolidated unaudited results on November 11, 2026.

Conclusion

Pharmaids moved from a Rs 7.81 crore consolidated first-half loss a year earlier to a Rs 6.24 lakh profit in the half year ended September 30, 2026. The result followed a Rs 4.20 crore exceptional item, while revenue fell to Rs 8.46 crore and the loss before exceptional items and tax remained Rs 4.16 crore. Lower expenses narrowed that underlying loss, but did not eliminate it.

The filing does not disclose the nature of the June-quarter exceptional item, leaving that a central unresolved matter for subsequent company disclosures. Readers can also monitor whether the September-quarter revenue increase of Rs 21.42 lakh over June continues, and how borrowings, which totalled Rs 25.50 crore across current and non-current categories at September 30, develop alongside operating cash flow of Rs 1.89 lakh.